证券代码：600881 证券简称：亚泰集团 公告编号：临 2023-049 号 吉林亚泰（集团）股份有限公司 关于为所属子公司提供担保的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 重要内容提示： ● 被担保人名称：吉林亚泰恒大装饰工程有限公司、吉林亚泰 富苑购物中心有限公司、海南亚泰温泉酒店有限公司。 ●本次担保金额及已实际为其提供的担保余额： 1．公司本次为吉林亚泰恒大装饰工程有限公司提供担保金额为 人民币 7,100 万元；截至本公告日，公司已实际为其提供的担保余 额为人民币 1.01 亿元。 2．公司本次为吉林亚泰富苑购物中心有限公司提供担保金额为 人民币 1.2 亿元；截至本公告日，公司已实际为其提供的担保余额 为人民币 5.98 亿元。 3．公司本次为海南亚泰温泉酒店有限公司提供担保金额为人民 币 1,000 万元；截至本公告日，公司已实际为其提供的担保余额为 人民币 1.2 亿元。 ● 上述担保无反担保。 1 一、担保情况概述 根据所属子公司经营需要，同意继续为吉林亚泰恒大装饰工程 有限 ...

证券代码：600881 证券简称：亚泰集团 公告编号：临 2023-028 号 吉林亚泰（集团）股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 会议召开时间：2023 年 5 月 19 日（星期五）下午 14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 12 日（星期五）至 5 月 18 日（星期四） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目进行提 问。公司将在说明会上对投资者普遍关注的问题进行回答。 吉林亚泰（集团）股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发布公司《2022 年年度报告》，为便于广大投资者更全 面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 5 月 19 日下午 14:00-15:00 举行 2022 年度业绩说明会，就投资者 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,608,455,332.98, representing a decrease of 41.45% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of CNY 342,455,334.96, an increase in loss of 25.06% year-over-year[5] - The basic earnings per share were -CNY 0.11, reflecting a decrease of 21.43% year-over-year[6] - Total operating revenue for Q1 2023 was ¥1,608,455,332.98, a decrease of 41.5% compared to ¥2,747,348,713.27 in Q1 2022[26] - Net profit for Q1 2023 was a loss of ¥465,277,677.65, slightly improved from a loss of ¥481,012,476.40 in Q1 2022[27] - Total comprehensive income for Q1 2023 was a loss of ¥464,618,231.51, compared to a loss of ¥491,844,962.29 in Q1 2022[27] Cash Flow - The net cash flow from operating activities was CNY 1,597,603,162.75, showing an increase of 55.18% compared to the previous year[5] - The net cash flow from operating activities for Q1 2023 was ¥1,597,603,162.75, an increase of 55% compared to ¥1,029,547,324.54 in Q1 2022[30] - Cash inflow from financing activities totaled 12,662,144,280.59 RMB, compared to 11,009,699,900.00 RMB in the previous year, indicating a growth of approximately 15%[31] - The net increase in cash and cash equivalents was -193,319,948.56 RMB, compared to -106,898,521.48 RMB in the prior year[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 52,655,677,329.87, a decrease of 1.93% from the end of the previous year[6] - Total assets amounted to CNY 53.69 billion, down from CNY 53.89 billion, reflecting a decrease of CNY 201.05 million[36] - Total liabilities were ¥41.29 billion, down from ¥41.87 billion, representing a decrease of about 1.39%[24] - Total liabilities decreased slightly to CNY 41.87 billion from CNY 42.06 billion, a reduction of CNY 193.37 million[36] - Total equity attributable to shareholders decreased marginally to CNY 9.62 billion from CNY 9.63 billion, a change of CNY 4.68 million[36] Investments - Investment income increased by 314.39%, primarily due to increased investment income from associated companies[7] - The company reported an investment income of ¥144,745,345.80 in Q1 2023, compared to a loss of ¥67,514,490.22 in Q1 2022[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 100,596[10] - The largest shareholder, Changchun Municipal Government State-owned Assets Supervision and Administration Commission, holds 295,088,616 shares, accounting for 9.08% of total shares[10] Strategic Agreements - On April 21, 2023, the company signed a strategic cooperation framework agreement with Jackdaw Capital Ltd to enhance collaboration in the pharmaceutical industry and financial operations[15] Other Financial Metrics - The company reported a net loss of ¥2.84 billion in retained earnings, worsening from a loss of ¥2.50 billion previously[24] - Research and development expenses increased to ¥16,608,411.20 in Q1 2023, up 225.5% from ¥5,106,211.82 in Q1 2022[26] - The company executed new accounting standards starting January 1, 2023, impacting the financial statements[31]

Financial Performance - In 2022, the company's operating revenue was approximately CNY 12.97 billion, a decrease of 34.02% compared to CNY 19.65 billion in 2021[21]. - The net profit attributable to shareholders of the listed company was a loss of approximately CNY 3.45 billion, a decline of 175.42% from a loss of CNY 1.25 billion in 2021[21]. - The net cash flow from operating activities improved to a negative CNY 742.20 million, a 9.56% increase compared to a negative CNY 820.61 million in 2021[21]. - The total assets at the end of 2022 were approximately CNY 53.69 billion, down 4.76% from CNY 56.38 billion at the end of 2021[21]. - The net assets attributable to shareholders of the listed company decreased by 26.43% to approximately CNY 9.62 billion from CNY 13.08 billion in 2021[21]. - The basic earnings per share for 2022 was -CNY 1.06, a decrease of 171.79% compared to -CNY 0.39 in 2021[22]. - The weighted average return on equity was -30.43%, a decrease of 21.43 percentage points from -9% in 2021[22]. - The company reported no cash dividend distribution for 2022 due to negative distributable profits[5]. Operational Challenges - The company faced significant challenges due to a 203-day cumulative work stoppage in the construction materials sector, leading to decreased cement production and prices[34]. - The company incurred an asset impairment provision of CNY 1,709,000,000 during the reporting period, including CNY 961,000,000 for credit impairment losses on receivables[34]. - The company reported a decrease in investment income of CNY 453,000,000, a decline of 70% compared to the previous year[34]. - The company faced significant challenges in 2022 due to asset impairment provisions and underperformance in core business operations, leading to a substantial deviation from its revenue targets[108]. Sector Performance - The construction materials sector generated revenue of RMB 5,191,843,241.52, down 15.69% year-on-year, with a gross margin of only 1.06%[46]. - The pharmaceutical sector reported revenue of RMB 2,145,857,618.22, with a gross margin of 44.90%, despite a 10.22% decline in revenue[46]. - The coal industry saw a significant revenue increase of 40.08% to RMB 947,971,344.59, but the gross margin fell by 8.39 percentage points to 7.47%[46]. - The company reported a revenue of 11,787 million RMB from the oncology sector, with a gross margin of 76.82%, reflecting a year-on-year increase of 1.60%[78]. - The company achieved a total of 14,714 million RMB in revenue from the cardiovascular sector, with a gross margin of 82.75%[78]. - The company reported a decrease in revenue from the gynecology sector, with a revenue of 7,470 million RMB, reflecting a year-on-year decline of 22.84%[78]. Strategic Initiatives - The company plans to focus on future development strategies, although specific commitments were not disclosed[6]. - The company is actively pursuing a "second high-quality entrepreneurship" strategy, focusing on construction materials, real estate, pharmaceuticals, and financial investments[37]. - The company aims to enhance its market share by expanding its sales channels, focusing on clinical sales and increasing coverage in chain pharmacies and grassroots medical institutions[85]. - The company aims to enhance cash flow management by focusing on rapid cash recovery, inventory reduction, and optimizing financing channels to lower costs and improve efficiency[110]. - The company plans to strengthen its drug development process by enhancing project management, risk control, and establishing a monitoring mechanism for adverse drug reactions[110]. Investments and Acquisitions - The company acquired a 51.02% stake in Jilin Province Jin'an Construction Group for RMB 13.81 million[51]. - The company also purchased 100% of Jilin Yatai Innovation Construction Engineering Co., Ltd. for RMB 2 million[51]. - The company approved the acquisition of 100% equity of Jilin Yatai Innovative Construction Engineering Co., Ltd. on December 15, 2022[198]. - The company approved the transfer of 49% equity of Jilin Yatai Biopharmaceutical Co., Ltd. on March 28, 2023[200]. Human Resources and Governance - The total number of employees in the parent company is 107, while the main subsidiaries employ 16,960, resulting in a total of 17,067 employees[146]. - The company has a structured salary policy that adjusts compensation based on performance evaluations, ensuring alignment with both company and employee interests[148]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 21.7881 million yuan[133]. - The company has established a comprehensive training system, implementing annual training plans that include onboarding, corporate culture, and skills training[149]. Environmental and Compliance - The company has established a comprehensive internal control system, including various management regulations[158]. - The company has completed environmental impact assessments for all construction projects and obtained the necessary approvals[165]. - The company has installed high-efficiency dust collectors and denitrification devices at cement production sites to mitigate pollution[164]. - The company has committed to not engaging in competitive business with Northeast Securities, ensuring compliance with industry regulations[175]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[168].

2022 年第三季度报告 单位：元 币种：人民币 1 / 12 证券代码：600881 证券简称：亚泰集团 吉林亚泰（集团）股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期比 年初至报告 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|---------------------------|-------------------|--------------------- ...

2022 年半年度报告 公司代码：600881 公司简称：亚泰集团 吉林亚泰(集团)股份有限公司 2022 年半年度报告 1 / 179 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 未出席董事职务 未出席董事姓名 未出席董事的原因说明 被委托人姓名 董事 刘晓峰 工作原因 王化民 三、 本半年度报告未经审计。 四、 公司负责人宋尚龙、主管会计工作负责人张羽及会计机构负责人（会计主管人员）张羽声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的发展战略、未来计划等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、 ...

2021 年年度报告 公司代码：600881 公司简称：亚泰集团 吉林亚泰(集团)股份有限公司 2021 年年度报告 1 / 279 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 中准会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人宋尚龙、主管会计工作负责人张羽及会计机构负责人（会计主管人员）张羽声 明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经中准会计师事务所（特殊普通合伙）审计，2021 年母公司实现净利润-331,056,551.93 元， 加上年初未分配利润 540,547,068.79 元，减会计政策变更调整年初未分配利润 113,445,234.35 元，减 2021 年实际分配股利 64,978,271.76 元，加上其他综合收益结转-13,264,072.90 元，年 末可供分配利润合计为 17,80 ...

Financial Performance - The company's operating revenue for Q1 2022 was ¥2,747,348,713.27, representing a decrease of 6.99% compared to the same period last year[6]. - The net profit attributable to shareholders of the listed company was -¥456,975,287.57, a decline of 74.44% year-on-year[6]. - Basic earnings per share were -¥0.14, down 75.00% from the same period last year[9]. - Net profit for Q1 2022 was -¥481,012,476.40, compared to -¥367,523,569.97 in Q1 2021, reflecting a 30.8% increase in net loss[34]. - Total comprehensive income for Q1 2022 was -¥491,844,962.29, compared to -¥362,407,614.01 in Q1 2021[34]. Cash Flow - The net cash flow from operating activities was ¥1,029,547,324.54, an increase of 142.85% compared to the previous year[6]. - Cash flow from operating activities for Q1 2022 was ¥1,029,547,324.54, significantly up from ¥423,935,453.53 in Q1 2021[36]. - Net cash flow from investing activities was -34,981,891.98, compared to -28,642,298.74 in the previous period, indicating an increase in cash outflow[38]. - The net cash flow from financing activities was -1,101,463,954.04, compared to -411,299,529.79 in the previous period, reflecting a larger cash deficit[38]. - The company experienced a net decrease in cash and cash equivalents of -106,898,521.48, compared to -16,006,375.00 in the previous period[38]. Assets and Liabilities - Total assets at the end of the reporting period were ¥54,412,009,277.33, a decrease of 3.48% from the end of the previous year[9]. - Total current assets decreased to approximately RMB 28.10 billion from RMB 29.78 billion, representing a decline of about 5.6%[26]. - Total liabilities decreased to approximately RMB 38.66 billion from RMB 40.13 billion, a reduction of about 3.7%[29]. - The company's total assets were approximately RMB 54.41 billion, down from RMB 56.38 billion, reflecting a decrease of about 3.5%[26]. - The company's non-current liabilities decreased to approximately RMB 4.35 billion from RMB 4.78 billion, a decline of about 8.9%[29]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 103,861[14]. - The largest shareholder, Changchun Municipal Government State-owned Assets Supervision and Administration Commission, holds 9.08% of the shares[14]. Income and Expenses - The company reported non-operating income of ¥9,009,849.65 after tax, primarily from government subsidies[10]. - The company experienced a significant increase in other income by 86.43%, mainly due to an increase in government subsidies received[10]. - Research and development expenses for Q1 2022 were ¥5,106,211.82, down 47.3% from ¥9,657,089.79 in Q1 2021[30]. - The company reported an investment loss of -¥67,514,490.22 in Q1 2022, contrasting with a gain of ¥121,585,150.42 in Q1 2021[30]. Inventory and Receivables - Accounts receivable stood at approximately RMB 6.11 billion, down from RMB 6.42 billion, reflecting a decrease of about 5%[22]. - The company's inventory was approximately RMB 10.97 billion, down from RMB 11.29 billion, indicating a decrease of about 2.8%[26]. Future Plans - The company plans to continue increasing its stake in Jilin Yatai Group, with a minimum of 10 million shares to be acquired in the next 12 months[18]. - The company completed the transfer of 100% equity in Jilin Yatai Vocational Training School, enhancing its training capabilities[21].

Financial Performance - The company's operating revenue for Q3 2021 was ¥6,222,780,224.68, representing a year-on-year increase of 30.86%[7] - The net profit attributable to shareholders for the same period was ¥10,734,278.46, showing a significant decrease of 65.37% compared to the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥497,006.58, an increase of 101.24% year-on-year[7] - The basic earnings per share for Q3 2021 was ¥0.0033, down 67.00% from the same period last year[9] - Total operating revenue for the first three quarters of 2021 reached ¥15,980,230,398.40, an increase of 22.4% compared to ¥13,089,913,608.36 in the same period of 2020[32] - Net profit for the first three quarters of 2021 was ¥34,770,960.15, compared to ¥29,555,542.07 in the same period of 2020, reflecting an increase of 17.5%[34] - The total comprehensive income for the first three quarters of 2021 was ¥40,348,356.43, compared to ¥31,623,768.66 in the same period of 2020, indicating a growth of 27.6%[34] - Basic earnings per share for the first three quarters of 2021 were ¥0.01, down from ¥0.05 in the same period of 2020[34] Cash Flow and Assets - The company's cash flow from operating activities was negative at -¥1,693,805,097.02 for the year-to-date, reflecting a significant cash outflow[9] - The company reported a net cash outflow from operating activities of ¥1,693,805,097.02 for the first three quarters of 2021, compared to a smaller outflow of ¥142,035,469.80 in the same period of 2020[37] - Cash received from operating activities totaled ¥18,638,398,381.81 in the first three quarters of 2021, compared to ¥14,836,911,646.20 in the same period of 2020, representing an increase of 25.5%[37] - The company's cash and cash equivalents decreased to approximately ¥4.42 billion from ¥9.21 billion, representing a decline of 52.0%[23] - The ending balance of cash and cash equivalents was $449,240,126.81, down from $2,793,463,487.19 at the end of the previous period[40] - Total assets at the end of the reporting period were ¥56,946,375,118.22, a decrease of 2.35% compared to the end of the previous year[9] - Total assets increased to $59,396,521,555.39 from $58,317,991,463.97, reflecting growth in the company's asset base[45] - Current liabilities increased to $36,987,026,791.66 from $36,764,566,809.80, suggesting a rise in short-term obligations[45] Liabilities and Equity - Total liabilities decreased to approximately ¥38.76 billion from ¥40.22 billion, a reduction of 3.6%[29] - The company's total equity increased to approximately ¥18.19 billion, up from ¥18.09 billion, reflecting a growth of 0.6%[29] - Total liabilities amounted to approximately $40.22 billion, a decrease of $1.08 billion compared to the previous period[47] - Total equity attributable to shareholders reached approximately $14.57 billion, remaining unchanged from the previous period[47] - Non-current liabilities totaled approximately $3.46 billion, down from $4.32 billion, indicating a reduction of approximately $856 million[47] Research and Development - Research and development expenses increased by 142.25% due to higher investment in building materials product development[13] - Research and development expenses increased significantly to ¥142,537,266.39 in the first three quarters of 2021, compared to ¥58,840,079.34 in the same period of 2020, marking an increase of 142.5%[32] Shareholder Information - The company reported a total of 94,441 common shareholders at the end of the reporting period[14] - As of October 8, 2021, Anhui Conch Cement Co., Ltd. purchased 162,445,690 shares of the company, representing 5.00% of the total issued shares[19] - The company reported a total of 295,088,616 shares held by the Changchun Municipal Government State-owned Assets Supervision and Administration Commission[18] - The company has a total of 161,958,390 shares held by Anhui Conch Cement Co., Ltd.[18] - The company has a total of 160,165,990 shares held by Wan Zhongbo[18] - The company has a total of 155,009,212 shares held by Jilin Jinta Investment Co., Ltd.[18] - The company has a total of 148,936,170 shares held by Wuxi Shengbang Real Estate Investment Co., Ltd.[18] - The company has a total of 129,477,298 shares held by Century Rongshang Information Technology Co., Ltd.[18] - The company has a total of 108,482,368 shares held by Tangshan Jidong Cement Co., Ltd.[18] Investments and Acquisitions - The company acquired 100% equity of Jilin Yatai Municipal Engineering Co., Ltd. for RMB 24.6 million, which has total assets and liabilities of 0 as of June 30, 2021[19] - The company established Harbin Yatai Longhua Trading Co., Ltd. with an investment of RMB 50 million, focusing on coal, steel, and building materials sales[19] Tax and Expenses - The company’s tax expenses for the first three quarters of 2021 were ¥149,077,826.65, compared to ¥121,562,741.94 in the previous year, reflecting an increase of 22.6%[34] Accounting Standards - The company has implemented the new accounting standard for leases since January 1, 2021, affecting the measurement of lease liabilities and right-of-use assets[49]

2021 年半年度报告 公司代码：600881 公司简称：亚泰集团 吉林亚泰（集团）股份有限公司 2021 年半年度报告 1 / 155 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 | --- | --- | --- | --- | |----------------|----------------|----------------------|--------------| | | | | | | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | 董事 | 翟怀宇 | 工作原因 | 王化民 | | 独立董事 | 王立军 | 工作原因 | 邴 正 | 三、 本半年度报告未经审计。 四、 公司负责人宋尚龙、主管会计工作负责人张羽及会计机构负责人（会计主管人员）张羽声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风 ...